Skip to main content
. 2021 Jul 2;100(26):e26529. doi: 10.1097/MD.0000000000026529

Table 1.

Baseline characteristics of T2DM patients with and without sarcopenia.

Parameters Non-sarcopenic (n = 67, 74.4%) Sarcopenic n = 23, 25.6%) P
Age (years) 55.01±8.81 54.17 ± 7.68 .685
Gender n, (%)
 Female 50 (71.4) 20 (28.6) .201
 Male 20 (85.0) 3 (15.0)
DM duration (years) 10.97 ± 6.74 11.26 ± 6.03 .848
Smoking, n (%) 4 (6.0) 1 (4.3) .909
Education level, n (%)
 ≤ Elementary school 50 (74.6) 20 (87.0) .201
 ≥Elementary school 17 (25.4) 3 (13.0)
Medication, n (%)
 OAD 26 (38.8) 7 (30.4) .468
 Insulin 41 (61.2) 16 (69.6) .617
 Statin 43 (64.2) 16 (69.6) .962
MIVC, n (%)
 Neuropathy 36 (53.7) 13 (56.5) .816
 Retinopathy 17 (25.4) 9 (39.1) .217
 Nephropathy 3.0 (4.5) 1.0 (4.3) .731
MAVC, n (%)
 ASCVD 19 (28.4) 8 (34.8) .189
 PAD 1 (1.5) 1 (4.3) .633
 CVD 1 (1.5) 1 (4.3) .633
Comorbidities, n (%)
 Hypertension 40 (59.7) 14 (60.9) .921
 Hyperlipidemia 46 (68.7) 18 (78.3) .371
 Obesity 52 (77.6) 21 (91.3) .125
Diabetes self-management, n (%)
 SMBG 39 (58.2) 14 (60.9) .823
 Diet compliance 32 (47.8) 11 (47.8) .996
 Exercises 23 (34.3) 7 (30.4) .802

Data are presented as n (%) and mean ± standard deviation.

T2DM = Type 2 Diabetes Mellitus; OAD = oral antidiabetics; MIVC = microvascular complications; MAVC = macrovascular complications; ASCVD = atherosclerotic cardiovascular disease; PAD = peripheral arterial disease; CVD = cerebrovascular disease; SMBG = Self Management Blood Glucose Monitoring.